{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:53:04Z","timestamp":1789228384132,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the randomized, phase 3, SUSA\u2010301 trial, celecoxib\u2010tramadol co\u2010crystal (CTC) provided significantly greater analgesia compared with celecoxib, tramadol, or placebo in adults with acute, moderate\u2010to\u2010severe, postoperative pain. This post hoc, secondary analysis further evaluated the use of rescue medication and the incidence of treatment\u2010emergent adverse events (TEAEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (<jats:italic>N<\/jats:italic>\u2009=\u2009637) were randomized 2:2:2:1 to receive oral CTC 200\u2009mg twice daily (BID; <jats:italic>n<\/jats:italic>\u2009=\u2009184), tramadol 50\u2009mg four times daily (QID; <jats:italic>n<\/jats:italic>\u2009=\u2009183), celecoxib 100\u2009mg BID (<jats:italic>n<\/jats:italic>\u2009=\u2009181), or placebo QID (<jats:italic>n<\/jats:italic>\u2009=\u200989). Post hoc analyses were conducted on the use of rescue medications up to 4 and 48\u2009h post\u2010study drug dose, stratified by baseline pain intensity (moderate\/severe), and on the incidence of TEAEs, stratified by rescue medication use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A significantly lower proportion of patients received any rescue medication within 4\u2009h post\u2010study dose with CTC (49.5%) versus tramadol (61.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0178), celecoxib (65.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0024), and placebo (75.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0001); this was also seen for oxycodone use. Fewer patients in the CTC group received \u22653 doses of rescue medication compared with the other groups, irrespective of baseline pain intensity. In patients who did not receive opioid rescue medication, CTC was associated with a lower incidence of nausea and vomiting TEAEs versus tramadol alone. In patients who received rescue oxycodone, the incidence of nausea was similar in the CTC and tramadol groups, and higher versus celecoxib and placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Celecoxib\u2010tramadol co\u2010crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate\u2010to\u2010severe, postoperative pain.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.13399","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:18:34Z","timestamp":1719980314000},"page":"1042-1050","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Celecoxib\u2010tramadol co\u2010crystal in patients with moderate\u2010to\u2010severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double\u2010blind, factorial, active\u2010 and placebo\u2010controlled trial"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-4396","authenticated-orcid":false,"given":"Eugene R.","family":"Viscusi","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-9196","authenticated-orcid":false,"given":"Oscar","family":"de Leon\u2010Casasola","sequence":"additional","affiliation":[{"name":"University of Buffalo\/Roswell Park Cancer Institute  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-8638","authenticated-orcid":false,"given":"Jes\u00fas","family":"Cebrecos","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2792-3166","authenticated-orcid":false,"given":"Adam","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Premier Research  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-8966","authenticated-orcid":false,"given":"Adelaida","family":"Morte","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7271-1141","authenticated-orcid":false,"given":"Esther","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-9271","authenticated-orcid":false,"given":"Mariano","family":"Sust","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-4619","authenticated-orcid":false,"given":"Anna","family":"Vaqu\u00e9","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4650-8470","authenticated-orcid":false,"given":"Ira","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Chesapeake Research Group LLC  Pasadena Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Daniels","sequence":"additional","affiliation":[{"name":"Optimal Research LLC  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Muse","sequence":"additional","affiliation":[{"name":"JBR Clinical Research  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9668-9532","authenticated-orcid":false,"given":"Michael E.","family":"Kuss","sequence":"additional","affiliation":[{"name":"Michael Kuss Consulting  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-1379","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Videla","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-1796","authenticated-orcid":false,"given":"Neus","family":"Gasc\u00f3n","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-7671","authenticated-orcid":false,"given":"Carlos","family":"Plata\u2010Salam\u00e1n","sequence":"additional","affiliation":[{"name":"Esteve Pharmaceuticals S.A.  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2276118"},{"key":"e_1_2_13_3_1","unstructured":"Kowa Pharmaceuticals America Inc.Seglentis: US prescribing information.2021. Accessed 26 June 2023. Available from:https:\/\/www.kowapharma.com\/documents\/SEGLENTIS_Prescribing_Information.pdf."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13136"},{"key":"e_1_2_13_5_1","unstructured":"Esteve Pharmaceuticals SA.Esteve announces FDA approval of a novel co\u2010crystal form of celecoxib and tramadol for the management of acute pain.2021. Accessed 3 May 2023. Available from:https:\/\/www.esteve.com\/uk\/news\/esteve\u2010announces\u2010fda\u2010approval\u2010of\u2010a\u2010novel\u2010co\u2010crystal\u2010form\u2010of\u2010celecoxib\u2010and\u2010tramadol\u2010for\u2010the\u2010management\u2010of\u2010acute\u2010pain."},{"key":"e_1_2_13_6_1","unstructured":"Esteve Pharmaceuticals SA.Velyntra Spanish regulatory approval.2023. Accessed 9 Oct 2023. Available from:https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/89051\/FT_89051.html."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.6b01848"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.04.002"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.9b00008"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13395"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13428"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.2021"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02744-2"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.08.014"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.13994"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2023-104412"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.4103\/joacp.JOACP_362_19"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-02686-2"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01594-X"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2023.02.037"},{"key":"e_1_2_13_21_1","unstructured":"United States Drug Enforcement Administration.Drug scheduling.2018. Accessed 24 July 2023. Available from:https:\/\/www.dea.gov\/drug\u2010information\/drug\u2010scheduling."},{"key":"e_1_2_13_22_1","unstructured":"Janssen Pharmaceuticals.Ultram: US prescribing information.2023. Accessed 21 Sept 2023. Available from:https:\/\/www.janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/ULTRAM\u2010pi.pdf."},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.370"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2211040"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.09.074"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.13399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:31:47Z","timestamp":1731324707000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.13399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/papr.13399"],"URL":"https:\/\/doi.org\/10.1111\/papr.13399","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"2024-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}